Latham Recognized With Six LMG Life Sciences Americas Awards Including Life Cycle Firm of the Year
Honors also include FDA Litigation & Enforcement Firm of the Year, Impact Case of the Year, and Impact Deal of the Year.
Daniel Rees, Global Vice Chair of Latham's M&A and Private Equity Practice, advises boards of directors and management teams on mergers and acquisitions, a broad range of other strategic corporate transactions, and provides general representation to public and private companies, including corporate and securities law matters, takeover defense, and securities offerings.
Daniel primarily represents companies in the healthcare and life sciences, technology, consumer products, and real estate industries. He also regularly represents top investment banks in their capacity as financial advisors in M&A transactions.
Daniel is widely recognized for his expertise in M&A. He was named one of the 500 Leading Dealmakers in the US by Lawdragon 500 in 2021, 2022, 2024, and 2025, recognized as a Top Healthcare Lawyer in North America in 2023 by MergerLinks, and was named a Rising Star for Mergers & Acquisitions by Super Lawyers Magazine for 2015, 2016, and 2017.
Daniel’s experience includes the representation of:
Honors also include FDA Litigation & Enforcement Firm of the Year, Impact Case of the Year, and Impact Deal of the Year.
Latham’s #1 rankings reinforce firm’s position as a global transactional powerhouse.
Recognitions include Impact Deal of the Year and Patent Impact Case of the Year.